CAJ | 학술논문

目的：探讨雄激素受体( androgen receptor, AR)在乳腺癌不同分子亚型中的表达及其与临床病理特征的关系。方法采用免疫组化EnVision两步法检测153例乳腺癌组织中雌激素受体( estrogen receptor, ER)、孕激素受体( progesterone recep-tor, PR)、HER-2、CK5/6、CK14表达,并依据免疫表型划分为Luminal A型、Luminal B型、HER-2过表达型、Basal-like型和Nor-mal-like型5个分子亚型,其分别为84、27、14、11和17例。对比分析AR在5个分子亚型中的分布及其与发病年龄、病理组织学分级、肿瘤大小、淋巴结状态及临床分期等的相关性。结果153例乳腺癌组织中AR的阳性率为73.20%,在5个分子亚型中以Luminal A型为主(62．50%)。在HER-2阴性与阳性乳腺癌中,AR的阳性率分别为75．00%和68．29%,两者间的表达差异无统计学意义(P=0．196)。在153例乳腺癌中有23例(15．03%)三阴型乳腺癌(ER、PR和HER-2均阴性),有15例(9．80%)乳腺癌ER、PR、AR均阴性,有8例(5．23%)四阴型乳腺癌(ER、PR、AR和HER-2均阴性)。 AR在ER/PR阳性与阴性乳腺癌之间的表达差异有统计学意义(P=0．001),与ER/PR表达呈正相关(rs =0．874,P=0．024)。 AR在组织学分级之间的表达差异有统计学意义(P=0．022),与组织学分级呈负相关(rs =-0．201,P=0．013)。 AR阳性与肿瘤大小有关,与淋巴结转移(P=0．211)及临床分期无关(P=0．065)。结论 AR在乳腺癌组织中的表达及其与临床病理特征的关系为进一步改善乳腺癌的分子分型提供依据,也为临床治疗及判断预后提供理论基础。
목적：탐토웅격소수체( androgen receptor, AR)재유선암불동분자아형중적표체급기여림상병리특정적관계。방법채용면역조화EnVision량보법검측153례유선암조직중자격소수체( estrogen receptor, ER)、잉격소수체( progesterone recep-tor, PR)、HER-2、CK5/6、CK14표체,병의거면역표형화분위Luminal A형、Luminal B형、HER-2과표체형、Basal-like형화Nor-mal-like형5개분자아형,기분별위84、27、14、11화17례。대비분석AR재5개분자아형중적분포급기여발병년령、병리조직학분급、종류대소、림파결상태급림상분기등적상관성。결과153례유선암조직중AR적양성솔위73.20%,재5개분자아형중이Luminal A형위주(62．50%)。재HER-2음성여양성유선암중,AR적양성솔분별위75．00%화68．29%,량자간적표체차이무통계학의의(P=0．196)。재153례유선암중유23례(15．03%)삼음형유선암(ER、PR화HER-2균음성),유15례(9．80%)유선암ER、PR、AR균음성,유8례(5．23%)사음형유선암(ER、PR、AR화HER-2균음성)。 AR재ER/PR양성여음성유선암지간적표체차이유통계학의의(P=0．001),여ER/PR표체정정상관(rs =0．874,P=0．024)。 AR재조직학분급지간적표체차이유통계학의의(P=0．022),여조직학분급정부상관(rs =-0．201,P=0．013)。 AR양성여종류대소유관,여림파결전이(P=0．211)급림상분기무관(P=0．065)。결론 AR재유선암조직중적표체급기여림상병리특정적관계위진일보개선유선암적분자분형제공의거,야위림상치료급판단예후제공이론기출。
Purpose To investigate the expression of androgen receptor ( AR) in molecular subtypes of breast cancer and its relation-ship with clinicopathological features. Methods The expression of estrogen receptor (ER), progesterone receptor (PR), HER-2, CK5/6, CK14 in breast cancer was detected by EnVision immunohistochemical staining, and they further be divided into 84 Luminal A subtypes, 27 Luminal B subtypes, 14 HER-2 overexpression subtypes, 11 Basal-like subtypes, and 17 Normal-like subtypes, respec-tively. The distribution of AR in 5 molecular subtypes and its relationship with clinicopathological factors, such as age, histopathologi-cal grading, tumor size, lymph node status and clinical staging, were analyzed. Results In 153 cases of breast cancer, the positive rates of AR expression were 73. 20%, Luminal A was the majority ( 62. 50%) in 5 molecular subtypes. In the HER-2 negative and positive breast cancer, the positive rates of AR expression were 75. 00% and 68. 29% and the difference between the two groups was no statistical significant (P=0. 196). Of the 153 breast cancers, 23 (15. 03%) were triple-negative breast cancers (ER-, PR- and HER-2-), 15 (9. 80%) breast cancers were negative for ER, PR and AR, 8(5. 23%) breast cancers were quadruple negative (ER-, PR-, AR- and HER-2 -) . There was significant difference of the expression of AR in ER/PR positive and negative breast cancer (P=0. 001),it was positively correlated with ER/PR protein expression (rs =0. 874, P=0. 024). The difference of AR ex-pression between histological grading was statistically significance ( P=0. 022 ) , the expression of AR was negatively correlated with histopathologic grading (rs = -0. 201, P=0. 013). The positive expression of AR was related to tumor size, but not correlated with lymph node metastasis ( P=0. 211 ) and clinical staging ( P=0. 065 ) . Conclusion The expression of AR in breast cancer tissues and its relationship with clinicopathological features may provide a basis for the further improvement molecular typing of breast cancer, and also provide the theoretical basis for clinical treatment and judging prognosis.